The Endocannabinoid System’s Paradoxical Effect in Pain Relief

The endocannabinoid system helps regulate pain signaling, but that does not mean more cannabis will always produce more pain relief. Some surgical studies associate cannabis use with greater postoperative pain or higher pain-medicine requirements. Those findings deserve attention, while the explanation for them remains more complicated than simply calling the system “overactivated.”

How the Endocannabinoid System Participates in Pain

The endocannabinoid system includes signaling molecules made by the body, receptors such as CB1 and CB2, and enzymes that control those signals. Anandamide and 2-arachidonoylglycerol, often shortened to 2-AG, are important endocannabinoids. FAAH and MAGL help break down these molecules; their roles should not be described simply as producing the body’s endocannabinoids.

As discussed in a review of non-opioid analgesics and endocannabinoid signaling, several pathways can interact with this system. That biological complexity is a reason to study specific medicines and outcomes, not evidence that any product advertised as “balancing the ECS” will relieve pain.

Paracetamol and Ibuprofen Are Not Simply Cannabis-Like Medicines

Experimental research suggests that the paracetamol metabolite AM404 contributes to pain-related signaling involving cannabinoid and other pathways. A 2023 review of AM404 describes several proposed mechanisms, including effects involving TRPV1. This work does not establish that paracetamol works solely by activating cannabinoid receptors, or that adding cannabis improves its clinical effect.

Ibuprofen is a nonsteroidal anti-inflammatory drug. Its established pharmacology includes inhibiting cyclooxygenase enzymes and reducing prostaglandin formation. The non-opioid analgesic review also discusses experimental interactions with endocannabinoid metabolism, but notes that NSAID inhibition of FAAH is not particularly potent. It is an overstatement to present indirect ECS activation as the settled explanation for the pain relief produced by all these medicines.

What the Evidence Says About Pain After Surgery

The question raised by Touil and Lavand’homme’s 2019 article on cannabis hyperalgesia remains relevant: can cannabis use sometimes be associated with greater sensitivity to pain? Hyperalgesia means an increased response to a painful stimulus. It is not automatically established whenever a cannabis user reports a high postoperative pain score.

The 2023 ASRA Pain Medicine consensus guideline describes evidence that cannabis users may experience more pain after surgery and may need more opioids. It recommends counseling frequent users about potentially worse postoperative pain control. The guideline also identifies gaps in evidence rather than providing a universal cannabis dose at which pain sensitivity reverses.

Many underlying studies are observational. Pre-existing pain, other medicine use, the type of surgery, cannabis-use patterns, and withdrawal can complicate interpretation. An association between cannabis use and pain does not demonstrate that ECS dysregulation caused the outcome in an individual patient.

Chronic Pain Findings Do Not Automatically Apply to Surgery

An updated systematic review of cannabis-based products for chronic pain found small short-term improvements with some THC-containing preparations, chiefly in neuropathic pain, alongside increased common adverse effects. The findings differed by formulation, and longer-term evidence remained limited.

That evidence addresses a different clinical question from managing pain immediately after an operation. It does not establish that recreational cannabis prevents postoperative pain, replaces an anesthetic plan, or allows patients to reduce prescribed medicines without medical advice.

What to Discuss With Your Surgical Team

The American Society of Anesthesiologists advises patients to disclose cannabis use, including CBD products. Tell the team what you use, how you take it, how often, and when you last used it. These details can affect anesthesia, pain management, and recovery planning.

Ask for instructions before surgery about stopping or continuing products, particularly prescribed cannabinoid medicines. Do not assume one abstinence interval is suitable for every formulation or patient. Also discuss when it is appropriate to resume use after surgery and possible interactions with pain medicines or sedatives.

The practical lesson is to plan care around the person’s condition and actual exposure. The ECS is one part of pain biology; it is not a simple dial that patients can reliably turn up or down with cannabis.